(0.31%) 5 115.72 points
(0.31%) 38 357 points
(0.34%) 15 982 points
(-0.88%) $83.11
(5.77%) $2.03
(0.39%) $2 356.30
(0.50%) $27.67
(4.05%) $959.45
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States...
Stats | |
---|---|
本日の出来高 | 325.00 |
平均出来高 | 1 145.00 |
時価総額 | 97 450.00 |
EPS | $0 ( 2024-03-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-04-17 | Takeda Pharmaceutical Co Ltd | Sell | 1 000 000 | Series A Convertible Preferred Stock |
2023-01-27 | Pakianathan Deepika | Sell | 1 172 | Common Stock |
2023-01-23 | Sjogren Eric | Sell | 279 | Common Stock |
2023-01-23 | Kuriakose Emil | Sell | 79 | Common Stock |
2023-01-23 | Molineaux Susan | Sell | 526 | Common Stock |
INSIDER POWER |
---|
-50.73 |
Last 99 transactions |
Buy: 6 839 475 | Sell: 3 539 228 |
Calithera Biosciences Inc 相関
10 最も負の相関 | |
---|---|
HZNP | -0.916 |
RXDX | -0.913 |
SUMR | -0.912 |
HWCC | -0.911 |
VBNK | -0.905 |
ARNA | -0.903 |
SKYX | -0.898 |
MLVF | -0.896 |
TTCF | -0.894 |
CPRX | -0.89 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Calithera Biosciences Inc 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-3.78 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-3.78 |
FY | 2021 |
収益: | $9.75M |
総利益: | $9.75M (100.00 %) |
EPS: | $-31.16 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-26.20 |
Financial Reports:
No articles found.
Calithera Biosciences Inc
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。